EUVIMEDEUVIMED entdecken
Open Access

FDA-Approved Tedizolid Phosphate Prevents Cisplatin-Induced Hearing Loss Without Decreasing Its Anti-tumor Effect

Zhiwei Yao, Yu Xiao, Wen Li, Shuhui Kong, Hailong Tu, Siwei Guo, Ziyi Liu, Lushun Ma, Ruifeng Qiao, Song Wang, Miao Chang, Xiaoxu Zhao und 4 weitere

Journal of the Association for Research in Otolaryngology · 2024

DOI: 10.1007/s10162-024-00945-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the Association for Research in Otolaryngology, 2024. Verfasst von Zhiwei Yao und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Surgery, Tianjin Medical University General Hospital, Tianjin Medical University, No. 154 Anshan Road, Heping District, Tianj…. Hauptthemen laut MEDLINE: Cisplatin, Zebrafish, Hearing Loss, Oxazoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shandong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinZebrafishHearing LossOxazolesOrganophosphatesAntineoplastic AgentsAnimalsMiceUnited States Food and Drug AdministrationDrug ApprovalHair Cells, AuditoryUnited StatesOtotoxicityHumans

Stichwörter der Autor:innen

Anti-tumorCisplatinHearOtotoxicityTedizolid phosphate

Substanzen

CisplatinOxazolesOrganophosphatesAntineoplastic Agentstedizolid phosphate

Autor:innen und Institutionen

  • Department of Pediatric Surgery, Tianjin Medical University General Hospital, Tianjin Medical University, No. 154 Anshan Road, Heping District, Tianjin, 300052, China.
  • Medical Science and Technology Innovation Center, Shandong First Medical University, Jinan, 250117, China.
  • School of Life Science, Shandong University, Qingdao, 266237, China.
  • Medical Science and Technology Innovation Center, Shandong First Medical University, Jinan, 250117, China. liwenn@sdfmu.edu.cn.
  • Department of Otolaryngology-Head and Neck Surgery, Shandong Provincial ENT Hospital, Shandong University, Jinan, 250000, China.
  • Department of Otolaryngology-Head and Neck Surgery, Shandong Provincial ENT Hospital, Shandong University, Jinan, 250000, China. sdphxl@126.com.

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Shandong Province

Zitieren

APA

Yao, Z., Xiao, Y., Li, W., Kong, S., Tu, H., Guo, S., Liu, Z., Ma, L., Qiao, R., Wang, S., Chang, M., Zhao, X., Zhang, Y., Xu, L., Sun, D., & Fu, X. (2024). FDA-Approved Tedizolid Phosphate Prevents Cisplatin-Induced Hearing Loss Without Decreasing Its Anti-tumor Effect. Journal of the Association for Research in Otolaryngology. https://doi.org/10.1007/s10162-024-00945-2

Vancouver

Yao Z, Xiao Y, Li W, Kong S, Tu H, Guo S, et al. FDA-Approved Tedizolid Phosphate Prevents Cisplatin-Induced Hearing Loss Without Decreasing Its Anti-tumor Effect. Journal of the Association for Research in Otolaryngology. 2024. doi:10.1007/s10162-024-00945-2

BibTeX
@article{Yao2024,
  author = {Yao, Zhiwei and Xiao, Yu and Li, Wen and Kong, Shuhui and Tu, Hailong and Guo, Siwei and Liu, Ziyi and Ma, Lushun and Qiao, Ruifeng and Wang, Song and Chang, Miao and Zhao, Xiaoxu and Zhang, Yuan and Xu, Lei and Sun, Daqing and Fu, Xiaolong},
  title = {FDA-Approved Tedizolid Phosphate Prevents Cisplatin-Induced Hearing Loss Without Decreasing Its Anti-tumor Effect},
  journal = {Journal of the Association for Research in Otolaryngology},
  year = {2024},
  doi = {10.1007/s10162-024-00945-2}
}
Kostenlos starten →